SK C&C Partners with Ilseong IS to Create Pharmaceutical Adverse Event Reports Using AI

On the 10th, SK C&C signed a 'Partnership for Artificial Intelligence (AI) Digital Transformation (DX) Cooperation in the Pharmaceutical Sector' with Ilsung IS, a domestic pharmaceutical company.

Ilsung IS, established in 1954, is the first pharmaceutical company in Korea to introduce antibiotics.

The goal of this partnership is to apply generative AI, cloud, and big data technologies to Ilsung IS to improve work efficiency and reduce costs.

SK C&C members are demonstrating a demo version of the 'Generative AI Adverse Drug Reaction Report' using the enterprise AI solution 'Solur'.
[Photo by SK C&C]

First, the two companies decided to implement a 'Generative AI Drug Adverse Event Report' using SK C&C's enterprise AI solution 'Solur.'

Drug adverse event reports are created to collect various direct and indirect adverse cases of undesirable and unintended signs, symptoms, or diseases that occur during the administration or use of drugs, and to share them with domestic and international regulatory authorities and related organizations.

Under the domestic drug surveillance system, pharmaceutical companies are required to submit adverse event reports periodically or as needed. Pharmaceutical companies submit reports related to drug adverse events ranging from as few as 2-3 to several dozen per day.

Solur quickly organizes and prepares various adverse event data collected through multiple channels in various formats according to the report forms required by regulatory authorities and related organizations.

The two companies plan to actively utilize Solur in various drug surveillance tasks in the future.

They will establish a drug surveillance-related system in a cloud-native environment and implement a drug safety-specialized AI platform linked with a drug-related 'safety database.'

SK C&C plans to expand into global pharmaceutical markets such as Japan through this collaboration.

Park Jun, head of SK C&C's DX division, said, "Through generative AI, we will be able to minimize the risks of adverse events and create a safe drug use environment," adding, "We will support Ilsung IS to flexibly respond to changes in the pharmaceutical market through AI hyper-automation across various pharmaceutical work sites."